Samsung Bioepis Files Biosimilar Enbrel In South Korea
This article was originally published in PharmAsia News
Executive Summary
Samsung Bioepis has applied for the approval in South Korea of production and sales of SB4, its biosimilar version of Amgen Inc.’s arthritis blockbuster Enbrel (etanercept).